Can you describe the workflow between urology clinics and medical oncology at your practice when a patient's being considered for this therapy? And where is that collaboration most critical?

So the collaboration in muscle invasive bladder cancer, when you're thinking about perioperative therapy for patients, starts in the very beginning, actually.

And it's throughout the entire pendulum of care for perioperative treatment.

So as soon as a patient is diagnosed with muscle invasive bladder cancer or locally advanced bladder cancer, the combination of both urology, medical oncology integration becomes very key.

And the reason being is if it's earlier on where you're thinking surgery is a possibility for specifically stage two or stage three disease, then patients need to get their surgical intervention done upfront be evaluated by medical oncology to discuss which perioperative therapy would be best suited for them, whether it be n-portamavidotin, plenverlizumab, or a chemotherapy-based regimen with immunotherapy backbone potentially as well.

So that evaluation for medical oncology becomes very key.

Once patients are done with the neoadjuvant therapy, then they would go back to urology to talk about surgical resection, and then come back to medical oncology to finish the remainder of their therapy.

How do toxicities resulting from ADCs impact the surgery team? And how does the team ensure that those adverse effects don't delay surgery?